Top 100 Pharmaceuticals Companies Ranking 2026

All values are in USD Million

Rank	Company	Total Revenue 2025	%Change (from 2024)	EBIT/operating income 2025	%Change (from 2024)	Net Income	%Change (from 2024)	Total Assets 2025	%Change (from 2024)	R&D Expenses 2025	%Change (from 2024)
1	Janssen/ Johnson & Johnson¹	94193	0.06	32581	0.952	26804	0.906			14665	-0.149
2	Roche¹	77510	0.017	23280	0.377	17387	0.502	126886	-0.011	16824	-0.128
3	Eli Lilly¹	65179	0.447	25731	1.029	20640	0.949	112476	0.429	13337	0.213
4	Pfizer¹	62579	-0.016	7520	-0.063	7771	-0.032	208160	-0.025	10437	-0.036
5	AbbVie¹	61160	0.086	15075	0.65	4233	-0.012			9096	-0.289
6	AstraZeneca¹	58739	0.086	13743	0.374	10233	0.453	114074	0.096	14232	0.048
7	Novartis¹	54532	0.084	17644	0.213	13967	0.17	110949	0.085	11200	0.118
8	Bayer¹	53323	-0.022	-1260		-4235		122313	-0.057	6750	-0.071
9	Sanofi¹	51042	0.062	7422	-0.125	9186	0.397	148363	-0.045	9175	0.061
10	Novo Nordisk¹	49450	0.064	20425	-0.005	16389	0.014	86864	0.166	8326	0.083
11	Bristol-Myers Squibb¹	46756	-0.032	9328		7055		90038	-0.028	9951	-0.108
12	Abbott¹	44328	0.057	8053	0.18	6524	-0.513	86713	0.065	2942	0.034
13	GlaxoSmithKine¹	43774	0.041	10629	0.973	8427	1.131	81898	0.028	10084	0.176
14	Shanghai Pharmaceuticals Holdings Co¹	39701	0.03	1392	0.221	976	0.188	32641	0.054	328	-0.023
15	CR Pharma Segment¹	37740	0.046	1651	0.079	1351	0.149	16444	0.197
16	China Resource Pharma Segment¹	37740	0.046	1651	0.079	1351	0.149	40014	0.109	351	0.249
17	Amgen¹	36751	0.1	9080	0.251	7711	0.885	90586	-0.014	7272	0.219
18	Boehringer Ingelheim¹	32469	0.036							7433	0.023
19	Takeda²	29322	0.075	2193	0.6	691	-0.251
20	Gilead Sciences, Inc. ¹	28915	0.011	10022	5.03	8510	16.729	59023	0	5799	-0.018
21	Fresenius¹	26388	0.048	3036	0.043	2334	0.141	48433	-0.049	730	-0.019
22	Merck¹	21102	-0.003	3601	-0.012	2615	-0.061	51527	-0.001	2415	0.06
23	Teva¹	17258	0.043	2157		1418		40748	0.036	1013	0.015
24	CSL³	15558	0.051	4134	0.084	3136	0.155	39404	0.036	1359	-0.05
25	Regeneron¹	14343	0.01	3578	-0.103	4505	0.021	40559	0.074	5850	0.14
26	Viatris¹	14300	-0.03	-2663		-3515		37193	-0.104	966	0.194
27	Daiichi Sankyo²	12072	0.178	2124	0.569	1893	0.474	25635	0.159	2790	0.194
28	Vertex Pharmaceuticals¹	12001	0.089	4173		3953		25643	0.138	3910	0.077
29	Baxter Pharma¹	11244	0.057	-308		-957		20055	-0.222	518	-0.122
30	Bausch Health¹	10156	0.067	1813	0.173	157		26366	-0.006	629	0.021
31	Biogen¹	9891	0.022	1557	-0.183	1293	-0.208	29440	0.05	1779	-0.102
32	Zoetis Inc¹	9467	0.023	3360	0.072	2673	0.075	15467	0.086	698	0.017
33	UCB¹	9057	0.258	2279	0.471	1823	0.463	21245	0.047	2132	0.071
34	Grifols¹	8803	0.043	1455	0.043	586	1.352	23062	-0.079	498	0.109
35	Chugai Pharmaceutical Co., Ltd.²	8051	0.075	3988	0.121	2886	0.136	12964	0.065	1153	0.018
36	Servier¹	8026	0.162
37	Organon¹	6216	-0.029	3313	-0.108	187	-0.784			30	0.034
38	Sun Pharma²	6060	0.094	1528	0.24	1214	0.141	10232	0.077	0.4	0.032
39	Fosun Pharma¹	5810	0.014	382	-0.019	472	0.217	16802	0.022	562	0.101
40	Yunnan Baiyao¹	5766	0.029	845	0.057	721	0.085	6083	0.018	49	0.039
41	Eisai²	5283	0.046	282	-0.189	259	-0.158	9274	0.045	1016	-0.075
42	Galderma¹	5207	0.181	829	0.285	613	1.654	13393	0.062	245	-0.058
43	Incyte¹	5141	0.212	1515	23.686	1287	38.45	6958	0.278	2050	-0.214
44	Elanco¹	4715	0.062	-224		-232		13358	0.059	368	0.07
45	Sino Biopharma¹	4457	0.103	972	0.316	744	-0.165	5892	-0.016	821	0.153
46	Jiangsu Hengrui Pharmaceuticals¹	4428	0.13	1219	0.215	1080	0.218	9781	0.394	1221	0.06
47	Ipsen1	430¹	0.081	1514	0.166	1181	0.176	8117	0.077	882	0.098
48	STADA Arzneimittel AG¹	4300	0.06
49	Jazz Pharma¹	4268	0.049	-430		-356		11659	-0.029	783	-0.115
50	Octapharma¹	4258	0.05	675	0.085	530	0.028	6467	0.052	137	0.088
51	Perrigo Company Plc¹	4253	-0.028	-1122		-1425		8535	-0.115	95	-0.15
52	Argenx¹	4248	0.886	1054		1292	0.551	8683	0.4	1364	0.387
53	Chiesi ¹	4241	0.062							1035	0.068
54	Lundbeck¹	3941	0.119	844	0.613	511	0.016	8329	-0.097	783	0.088
55	Pierre Fabre¹	3744	0.046
56	Genmab¹	3720	0.192	1065	0.096	963	-0.15	12873	1.007	1606	0.136
57	Alnylam Pharma¹	3714	0.652	502		314		4966	0.171	1320	0.172
58	CSPC Pharma¹	3641	-0.104	673	-0.138	543	-0.107	6573	0.058	813	0.119
59	Aurobindo²	3594	0.094	563	0.157	387	0.099	5531	0.105	15	-0.412
60	Biontech¹	3358	0.043	-1229		-1329		25727	-0.024	2463	-0.066
61	Hikma¹	3349	0.071	741	0.031	508	0.02	5671	0.105
62	United therapeutics¹	3183	0.106	1493	0.084	1335	0.117	7880	0.07	550	0.143
63	Cipla²	3153	0.071	757	0.157	585	0.269	4150	0.143	170	-0.022
64	Ono²	3116	-0.031	382	-0.626	321	-0.608	6810	0.165	959	0.336
65	Sobi¹	3106	0.085	95	-0.846	52	-0.877	7418	-0.106
66	Recordati¹	3064	0.118	785	0.05	519	0.065	6145	0.023	399	0.192
67	Ferring¹	2945	0.074	196	-0.127	53	-0.672	4994	-0.081	418	-0.03
68	Celltrion¹	2872	0.17	806	1.375	712	1.462	15411	0.061
69	Neurocrine¹	2861	0.214	619	0.085	479	0.402	4632	0.245	1016	0.389
70	Neurocrine Biosciences¹	2861	0.214	619	0.085	479	0.402	4632	0.245	1016	0.389
71	Shionogi²	2805	0.007	1002	0.021	1085	0.056	9826	0.084	695	0.058
72	Dr. Reddy's²	2680	0.185	804	0.249	594	0.232	4254	0.261	268	0.206
73	Dainippon Sumitomo2	2553	0.268	184		151		3350	-0.189	319	-0.557
74	Lupin²	2545	0.138	446	0.658	367	0.708	3245	0.217	196	0.158
75	Royalty Pharma¹	2378	0.05	1560	0.207	1324	-0.005	19621	0.077	452	225
76	Exelixis¹	2320	0.07	872	0.443	783	0.501	2844	-0.035	825	-0.094
77	Orion¹	2211	0.225	739	0.516	585	0.517	2351	0.234	246	0.171
78	Sarepta Therapeutics¹	2198	0.156	-700		-713		3350	-0.155	1522	0.892
79	Hansoh Pharma¹	2104	0.226	917	0.288	778	0.271	5586	0.26	470	0.243
80	Moderna¹	1944	-0.399	-2728		-2822		12338	-0.128	3132	-0.311
81	Kedrion¹	1931	0.046
82	Santen¹	1920	-0.006	304	0.589	229	0.343	2619	-0.061	154	-0.052
83	Zydus²	1757	0.328	827	0.756	642	0.678	3590	0.342
84	Biocon²	1696	0.034	486	0.051	113	-0.009	6532	0.049	95	-0.256
85	Changchun Tech¹	1692	-0.103			-3
86	Otsuka¹	1580	-0.894	3068	0.482	2344	0.055	26864	0.123	2258	0.123
87	Keenova¹	1431	0.32	-348		-490		5629	0.704	91	0.016
88	Halozyme Therapeutics¹	1397	0.376	469	-0.15	317	-0.286	2525	0.224	81	0.031
89	Torrent Pharma²	1282	0.07	297	0.136	212	0.154	1665	-0.005	65	0.102
90	Zhifei Bio¹	1254	-0.656			-2061		4441	-0.382	131	-0.087
91	Ionis¹	944	0.338	-382		-381		3524	0.173	916	0.016
92	Ascendis Pharma¹	843	0.98	-249		-267		1524	0.104	355	-0.011
93	Emergent BioSolutions¹	743	-0.288	100		53		1319	-0.051	53	-0.248
94	Tianjin Pharmaceuticals Da Ren Tang Group Corp¹	688	-0.327	348	-0.035	296	-0.047	27	0.169	635	0.09
95	Gan& Lee Pharma¹	567	0.331	166	0.874	172	0.951	1768	0.049	91	0.196
96	SK Biopharma¹	488	0.291	141	1.117	175	0.116	827	0.156
97	PharmaMar¹	257	0.256	65	1.521	77	0.635	521	0.085
98	CanSino Biologics¹	148	0.284	6		4		1005	-0.098	44	-0.248
99	Astellas²	12	0.192	3	0.417	0.3	1.982	21373	-0.064	2	0.114
100	WuXi AppTec¹	6	0.158			3	1.052	14	0.284	148	-0.055

^[1] Year Ending December 2025
^[2] Year Ending March 2025
^[3] Year Ending June 2025

The Top 100 Pharmaceutical Manufacturing Companies Ranking 2026, published by ChemAnalyst, presents a comprehensive assessment of the world's leading pharmaceutical manufacturers based on their financial performance during the fiscal year 2025. The ranking serves as a benchmark for evaluating the competitive landscape of the global pharmaceutical industry by analyzing the financial strength, operational efficiency, innovation capabilities, and overall business performance of the industry's key players. As the pharmaceutical sector continues to evolve in response to changing healthcare demands, technological advancements, demographic shifts, and regulatory developments, this ranking provides valuable insights into the companies that have demonstrated exceptional resilience and sustained growth during the year.

The 2026 edition highlights the remarkable transformation taking place across the pharmaceutical industry. The year 2025 witnessed continued expansion in demand for innovative therapies, particularly in obesity, diabetes, oncology, immunology, rare diseases, and specialty medicines, while demand for COVID-19-related products continued to normalize. Companies with diversified product portfolios and strong innovative pipelines significantly outperformed peers that remained dependent on pandemic-related revenues. At the same time, increasing investments in biologics, gene therapies, precision medicine, and artificial intelligence-driven drug discovery continued to reshape the industry's long-term growth trajectory.

The ranking has been developed using publicly available financial statements and annual reports released by the respective companies for fiscal year 2025. To provide a holistic evaluation of corporate performance, ChemAnalyst analyzed five key financial indicators, namely Revenue, Operating Income, Net Income, Total Assets, and Research & Development (R&D) Expenditure. These parameters collectively reflect a company's commercial scale, operational efficiency, profitability, financial stability, and commitment to innovation. While revenue and profitability indicate market success and operational excellence, total assets demonstrate financial strength, whereas R&D expenditure highlights an organization's ability to sustain future growth through continuous product development and technological advancement.

Top Performers

ChemAnalyst has conducted a comprehensive analysis and ranking of companies based on their performance, considering key indicators such as Revenue, Business Operating Income, Net Income, Total assets, and R&D expenditure in 2026 compared to 2025.

Top 10 Companies by Revenue

The global pharmaceutical industry continued to demonstrate strong financial resilience in 2025, supported by robust demand for innovative therapies, expanding biologics portfolios, increasing adoption of obesity and diabetes treatments, and continuous investments in research and development. Among the major pharmaceutical companies, Johnson & Johnson (J&J) remained the leading revenue generator, reporting annual sales of USD 94.2 billion, reflecting solid growth across its pharmaceutical and MedTech divisions. Eli Lilly emerged as one of the industry's strongest performers, recording a remarkable 45% increase in revenue to approximately USD 65.2 billion, primarily driven by exceptional demand for Mounjaro and Zepbound. Pfizer reported revenue of around USD 62.6 billion, although declining sales of COVID-19 products weighed on overall performance. Roche generated CHF 61.5 billion in revenue as strong demand for its pharmaceutical and diagnostic products offset macroeconomic challenges.

Similarly, AbbVie reported total revenue of USD 61.2 billion, supported by rapid growth in its immunology portfolio, particularly Skyrizi and Rinvoq. AstraZeneca generated USD 58.7 billion in revenue, driven by strong performances across oncology, cardiovascular, and rare disease segments, while Novartis recorded revenue of USD 54.5 billion, benefiting from continued expansion within its oncology portfolio. Bristol-Myers Squibb (BMS) generated USD 48.2 billion in revenue as growth in Opdivo and Yervoy partially offset declines in other therapeutic categories. Bayer and Sanofi reported annual revenues of EUR 45.6 billion and EUR 43.6 billion, respectively, while GSK generated GBP 32.7 billion through sustained growth in its respiratory, oncology, and HIV businesses. Gilead Sciences and Amgen reported revenues of USD 29.4 billion and USD 25.7 billion, respectively, whereas Novo Nordisk reported revenue of DKK 309.1 billion, driven by exceptionally strong demand for Ozempic, Wegovy, and Rybelsus. Overall, the sector benefited from favorable pricing strategies, expanding product pipelines, and increasing global healthcare expenditure.

Top 10 Companies by Business Operating Income

Operating profitability improved considerably across the pharmaceutical industry during 2025 as companies focused on improving manufacturing efficiency, optimizing supply chains, increasing production capacity, and implementing cost-control measures. Johnson & Johnson recorded the strongest performance among the companies considered, with operating income increasing to USD 32.6 billion, nearly doubling compared with the previous year as a result of stronger margins and favorable tax adjustments. Novartis generated operating income of USD 17.6 billion, benefiting from increased demand for high-value oncology products and improvements in operational efficiency. Amgen reported non-GAAP operating income of approximately USD 16.2 billion, while AstraZeneca generated operating income of USD 13.7 billion, supported by strong product sales and the absence of major one-time charges that had affected previous financial results.

Likewise, Sanofi reported business operating income of approximately EUR 12.1 billion, while Bayer recorded EBITDA before special items amounting to EUR 9.7 billion, although profitability remained under pressure because of portfolio restructuring costs and litigation-related expenses. GSK generated operating profit of GBP 7.9 billion, supported by lower legal expenses and higher royalty income. Novo Nordisk reported operating profit of DKK 127.7 billion, despite the negative impact of restructuring expenses. Meanwhile, Roche, Eli Lilly, and Gilead Sciences also recorded substantial improvements in operating profitability owing to higher sales volumes, favorable product mixes, and lower impairment charges. Overall, the pharmaceutical industry maintained strong operating margins as companies continued to prioritize high-value products and optimize cost structures.

Top 10 Companies by Net Income

Most leading pharmaceutical companies reported significant growth in net earnings during 2025, reflecting strong revenue generation, improved operating efficiency, and the absence of major impairment charges that had negatively affected financial performance in previous years. Johnson & Johnson reported net income of USD 26.8 billion, representing an increase of more than 90% compared with the previous year. Eli Lilly reported net income of USD 20.6 billion, nearly doubling its profitability as sales of diabetes and obesity medications continued to surge. Novartis generated net earnings of approximately USD 14.0 billion, while Roche recorded net income of CHF 13.8 billion, supported by strong operational performance and reduced impairment expenses.

Similarly, Novo Nordisk reported net profit of DKK 104.4 billion, benefiting from increasing demand for its flagship products. AstraZeneca generated net earnings of USD 10.2 billion, while Sanofi reported net income of approximately EUR 7.8 billion. Pfizer, Bristol-Myers Squibb, Amgen, Gilead Sciences, and AbbVie recorded net profits of USD 7.8 billion, USD 7.1 billion, USD 6.8 billion, USD 4.1 billion, and approximately USD 4.1 billion, respectively. In contrast, Bayer reported a net loss of approximately EUR 3.6 billion, reflecting the continued financial impact of legal settlements and impairment charges. Although GSK did not disclose its exact net income figures, the company reported a substantial improvement in earnings per share owing to favorable tax adjustments and the absence of significant one-time charges. Overall, the sector demonstrated remarkable resilience despite inflationary pressures, geopolitical uncertainties, and increasing regulatory scrutiny.

Top 10 Companies by Total Assets

Leading pharmaceutical companies continued to strengthen their balance sheets in 2025 through acquisitions, strategic investments, cash accumulation, and continued expansion of manufacturing and research infrastructure. Johnson & Johnson maintained the industry's largest asset base, reporting total assets of approximately USD 199.2 billion, reflecting the effects of acquisitions and higher cash reserves. AstraZeneca, Eli Lilly, and Novartis reported total assets of USD 114.1 billion, USD 112.5 billion, and USD 110.9 billion, respectively, while Roche maintained total assets of approximately CHF 100.7 billion despite modest declines arising from currency fluctuations.

Amgen reported total assets amounting to USD 90.6 billion, while Bayer maintained assets of approximately EUR 90 billion, supported by its diversified pharmaceutical, crop science, and consumer health operations. Novo Nordisk significantly strengthened its financial position, reporting total assets of DKK 542.9 billion, representing an increase of more than 16% compared with the previous year. GSK reported total assets of GBP 61.1 billion, while Gilead Sciences maintained assets of approximately USD 26 billion. Financial data relating to the total assets of Pfizer, Sanofi, AbbVie, and Bristol-Myers Squibb were not available in the reported figures. Nevertheless, the industry as a whole continued to maintain strong balance sheets, enabling companies to pursue acquisitions, expand manufacturing capabilities, and support long-term research initiatives.

Top 10 Companies by R&D expenditure

Investment in research and development remained one of the defining characteristics of the pharmaceutical industry in 2025, as companies sought to strengthen their product pipelines, accelerate clinical trials, and expand into rapidly growing therapeutic areas such as oncology, immunology, gene therapy, and obesity management. Johnson & Johnson and AstraZeneca reported the highest research expenditures among the companies considered, allocating approximately USD 14.7 billion and USD 14.2 billion, respectively, toward innovation and product development. Eli Lilly increased its investment by more than 20%, reaching USD 13.3 billion, as the company accelerated the development of next-generation obesity and diabetes treatments.

Likewise, Roche, Novartis, and Pfizer invested approximately CHF 12.2 billion, USD 11.2 billion, and USD 10.4 billion, respectively, in research activities. Bristol-Myers Squibb and AbbVie reported expenditures of approximately USD 10.0 billion and USD 9.1 billion, respectively, while Amgen allocated USD 7.3 billion to support clinical trials and biosimilar development. GSK, Gilead Sciences, and Sanofi reported research expenditures of GBP 6.3 billion, USD 5.8 billion, and approximately EUR 2.3 billion, respectively. Meanwhile, Novo Nordisk increased its investment significantly, reporting research and development spending of DKK 52.0 billion, primarily to strengthen its diabetes and obesity portfolio. Although Bayer did not disclose a specific figure, the company continued to make substantial investments in pharmaceutical and agricultural biotechnology research. Overall, sustained research spending reflected the industry's commitment to innovation and its efforts to address evolving healthcare needs while maintaining long-term competitiveness.

Research Methodology

The methodology for analyzing and ranking the world's top pharmaceutical manufacturing companies in 2025 involved a comprehensive and systematic approach. Initially, a thorough list of major global pharmaceutical manufacturers was compiled, covering a wide range of companies from various regions and market segments. The primary source of data for this analysis was the annual reports of these companies for the year 2025, with a particular focus on their consolidated balance sheets and financial statements. The cornerstone of the ranking system was the companies' net revenue or sales figures for 2025. This metric was chosen as the primary ranking factor due to its clear representation of a company's market presence and overall financial performance. It's worth noting that the financial reporting periods varied slightly among companies, with some publishing reports for the fiscal year ending in 2025, while others for March 2025. To accommodate these differences, the methodology allowed for flexibility in the reporting periods while maintaining a focus on the most recent and relevant financial data. The scope of the report extended beyond purely pharmaceutical companies to include businesses with diverse operations, such as those involved in chemical manufacturing or medical equipment production. However, to maintain focus and relevance, the ranking primarily considered the performance of their pharmaceutical drugs segment when evaluating these multifaceted corporations.

A key aspect of the methodology was the evaluation of year-over-year performance improvement. This was calculated as the percentage change in key financial metrics from 2022 to 2023. The analysis incorporated several crucial financial indicators to provide a holistic view of each company's performance:

Sales or revenue: Reflecting the company's market performance and growth.
EBIT (Earnings Before Interest and Taxes) or Business Operating Income: Indicating operational profitability.
R&D (Research and Development) expenses: Highlighting investment in innovation and future growth.
Capital expenditure (CAPEX): Showing investment in long-term assets and infrastructure.
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): Providing insight into operational efficiency and cash flow.

For each of these metrics, the percentage difference between 2025 and 2024 was calculated, offering a clear picture of year-over-year growth or decline. This multi-faceted approach allowed for a nuanced understanding of each company's financial health and strategic positioning.

Note: It's important to note that in some cases, certain financial indicators had to be omitted from the analysis. This was due to inconsistencies in how different companies reported their financials, with some metrics not clearly presented in annual reports or press releases. This limitation was carefully considered to ensure that the analysis remained fair and consistent across all companies. Also, to create a level playing field for international comparison, all financial figures were converted to Million/Billion US dollars (US$). The conversion rate used was the average of 31st December 2025, ensuring that all companies were evaluated on the same currency basis, regardless of their home country or primary operational currency.

Disclaimer

The information provided in this ranking is intended to be informative and should not be relied upon as the sole factor in making any financial decisions. It is important to note that each country may have its own unique financial reporting regulations and that companies may use various methods to present their financial performance. Therefore, discrepancies in reported values may occur. While every effort has been made to generate this ranking using the most appropriate and relevant approach, any suggestions or feedback to improve its accuracy are welcome.

Get Real Time Prices